Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) — regulation 31
Jagsonpal Pharmaceuticals disclosed promoter shareholding details as of March 31, 2026 under SEBI Regulation 31(4). The filing confirms no encumrances on promoter shares during the financial year, with Infinity Holdings and promoter group entities reporting zero encumbrances. The filing was submitted to BSE and NSE for record-keeping purposes.
About Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
📡 Get AI alerts when JAGSNPHARM files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track JAGSNPHARM — Free💡 Ask AI about this filing
📊 More JAGSNPHARM filings
- 🔴 Corporate Action — 15 July 2026 Jagsonpal Pharmaceuticals announced the allotment of 94,000 equity shares of Rs. 2 each under its Em...
- Announcement — 8 July 2026 Jagsonpal Pharmaceuticals announced completion of acquiring 77.21% equity in Aequitas Healthcare, fa...
- share transfer — 6 July 2026 Jagsonpal Pharmaceuticals received a SEBI-mandated certificate from MCS Share Transfer Agent confirm...
- Announcement — 29 June 2026 Jagsonpal Pharmaceuticals announced it will acquire an 85% stake in Aequitas Healthcare Private Limi...
- Announcement — 29 June 2026 Jagsonpal Pharmaceuticals announced it will acquire an 85% stake in Aequitas Healthcare Private Limi...
🔥 Also filed on 30 June 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
📡 Get AI alerts when JAGSNPHARM files new disclosures
Track JAGSNPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track JAGSNPHARM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research